Portrait of Kanav Jain

Product leader · hands-on builder · Chicago · Open to relocation

I turn new AI capabilities into products that hospitals and other cautious institutions will deploy

calls on an average workday
300,000+
health systems using it
250+
since I left, still running
9 years

Doximity Dialer, which I originated as founding product lead. Doximity’s own figures, February 2026.

14 years as a product leader and hands-on builder, making products in clinical care, oncology and AI, after training in biomedical engineering and molecular-biology research. See where I’d fit →

DoximityEpicTranscarentCancerCompass / CTCA MarketplaceAndwiseMemorial Sloan Kettering Cancer CenterTechstars

The two products deal with one problem: records that go out of date while people still rely on them, like a guideline that no longer matches the evidence.

Inspect the engineering: Ambit, Refract, and Stims →

  • Refract Change tracking: records every edit to a source, such as a Wikipedia article, and what each edit changed. A published test set of 16,146 recorded edits, reproducible from the same source.
  • Fast Harm, Slow Repair Agent error evaluation: a draft benchmark protocol for measuring how far AI mistakes propagate through tools and what remains wrong after correction. No results yet.

I come in before there’s a roadmap, build an unproven idea far enough to see whether it holds, and then decide what to scale, what to cut, and who should own it.

I originated Doximity Dialer, led R&D at CancerCompass, and co-founded Andwise. Andwise showed in year one that physicians wanted it; I did not work out who would pay until year two, and by then every path that could fund growth made someone other than the physician the paying customer. I chose to wind down the company in 2024. Since then I have built NextConsensus, Ambit, and Refract, putting new AI capabilities into production alongside cross-functional teams.

Revised